Leading Clinicians to Present Data On Cypress Bioscience, Inc.'s Prosorba Column At the 62nd American College of Rheumatology Conference.SAN DIEGO--(BW HealthWire)--Nov. 9, 1998-- Prosorba(R) Column Recommended for Approval by FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. Advisory Panel For Use in Rheumatoid Arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. Unique Treatment May Provide Non-Drug Alternative To Currently Available Therapies Several leading clinicians present data on Cypress Bioscience, Inc.'s Prosorba(R) column at the American College American College is the name of:
rheu·ma·tol·o·gy n. conference in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , CA from November 9 - November 12, 1998. Two weeks ago, the Prosorba(R) column was recommended for approval by a FDA Advisory Panel as a treatment for moderate to severe rheumatoid arthritis (RA). Among the next generation of RA treatments, the Prosorba(R) column is the only non-drug, therapeutic medical device that is awaiting FDA approval. In clinical trials, patients that responded to Prosorba(R) column found relief from their symptoms without the help of second-line or DMARD Disease Modifying Anti-Rheumatic Drugs (DMARDs) A class of antirheumatic drugs, including chloroquine, methotrexate, cyclosporine, and gold compounds, that influence the disease process itself and do not only treat its symptoms. Mentioned in: Antirheumatic Drugs therapies, such as methotrexate methotrexate, drug used in halting the growth of actively proliferating tissues. Introduced in the 1950s, it is used in the treatment of leukemia, psoriasis, and non-Hodgkin's lymphoma. . The Prosorba(R) column has been found to remove certain antibodies from a patient's blood, and may have additional immunomodulatory effects which reduce the joint pain and swelling associated with RA. Cypress Bioscience, Inc. of San Diego, CA develops, manufactures and markets medical devices and therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. for the treatment of certain types of immune disorders and is engaged in the development of novel therapeutic agents for the treatment of blood platelet blood platelet n. See platelet. disorders. In addition to Cypress's lead product, the Prosorba(R) column, the Company acquired Cyplex(R) (Infusible in·fus·i·ble adj. Suitable for infusion; capable of being infused. in·fus  i·bil Platelet Membranes), which is
positioned to become an alternative for traditional platelet infusions.Except for historical information contained herein, this news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties, including, but not limited to, the Company's ability to receive regulatory approval for the Prosorba(R) column or Cyplex(R) (Infusible Platelet Membranes), a platelet alternative, on a timely basis, if at all; whether the Company will be successful in marketing the Prosorba(R) column for use as a treatment for RA; whether the Company will be successful in collaborating with a marketing partner or not; whether Cyplex(R) (Infusible Platelet Membranes), a platelet alternative, will become a substitute for traditional platelet infusions, as well as other risks detailed from time to time in the Company's SEC reports, including its report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 1997. -0-
WHAT: Cypress Bioscience Presentations at the
American College of Rheumatology Conference
WHERE: San Diego, CA - Various Locations
WHEN: Monday, November 9 to Thursday, November 12, 1998
CONTACT: Lena Kim, (212) 484-6706
--- Please See Attached Schedule of Events ---
Schedule of Cypress Bioscience, Inc. Presentations
62nd American College of Rheumatology Conference
ACR Abstract Concurrent Session, Wednesday, November 11, 2:45 p.m.,
Room 6B
Rheumatoid Arthritis: Clinical Aspects (1869)
Factors affecting response to treatment in rheumatoid arthritis
clinical trials.
J.J. Anderson, G. Wells, A.C. Verhoeven and D.T. Felson. Boston, MA;
Ottawa, Canada and Maastricht, The Netherlands.
ACR Concurrent Session, Thursday, November 12, 11:45 a.m., Room 6A
Rheumatoid Arthritis: Evolving Therapies II (1992)
Results of a randomized double blind trial of the Prosorba(R) column
for treatment of severe rheumatoid arthritis.
D. Felson, D. Furst, M. LaValley and M. Gendreau. Boston, MA;
Seattle, WA and San Diego, CA.
ACR Poster Session D, Tuesday, November 10, 12:30 p.m. - 2:00 p.m.
RHEUMATOID ARTHRITIS CLINICAL ASPECTS: PROGNOSIS AND OUTCOME (1044)
Alternative definitions of 20% response in rheumatoid arthritis
clinical trials with repeated measurements.
M.P. LaValley, S.R. Evans, M. Gendreau and D.T. Felson. Boston, MA and
San Diego, CA.
ACR Poster Session F, Wednesday, November 11, 12:30 p.m. - 2:00 p.m.
Rheumatoid Arthritis Treatment (1701)
Patients with severe rheumatoid arthritis responding to treatment
respond again on retreatment.
D.E. Furst, D. Felson and M. Gendreau. Seattle, WA; Boston, MA and
San Diego, CA.
Satellite Symposium, Thursday, November 12, 1:00pm to 4:00pm, Room 6C
Emerging Role of Apherisis with Protein A Immunoadsorption.
NOTE: Cypress will have a booth for the duration of the conference at
the San Diego Convention Center (Booth Number: I-839).
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion